Related Experiment Video
Updated: Oct 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
Masmudur M Rahman1, Grant McFadden1
1Center for Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
Abstract:
Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively targets and kills cancer cells while sparing normal ones. In the past several decades, many different OV candidates have been developed and tested in both laboratory settings as well as in cancer patient clinical trials. Many approaches have been taken to overcome the limitations of OVs, including engineering OVs to selectively activate anti-tumor immune responses. However, newer approaches like the combination of OVs with current immunotherapies to convert "immune-cold" tumors to "immune-hot" will almost certainly improve the potency of OVs. Here, we discuss strategies that are explored to further improve oncolytic virotherapy.
Insights
Oncolytic viruses (OVs) offer a novel cancer therapy by selectively destroying cancer cells. Combining OVs with immunotherapy may enhance treatment effectiveness, particularly for "immune-cold" tumors.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Cancer is a leading global cause of death with unmet therapeutic needs.
- Current treatments lack efficacy for many cancer types.
- Oncolytic viruses (OVs) show promise as a targeted cancer therapy.
Purpose of the Study:
- To review strategies for enhancing oncolytic virotherapy.
- To explore the potential of combining OVs with immunotherapy.
Main Methods:
- Development and testing of various OV candidates.
- Engineering OVs for enhanced anti-tumor immune responses.
- Investigating combination therapies with existing immunotherapies.
Main Results:
- OVs selectively target and eliminate cancer cells, sparing normal cells.
- Engineering OVs can improve their anti-tumor immune activation.
- Combining OVs with immunotherapy may convert "immune-cold" tumors to "immune-hot".
Conclusions:
- Oncolytic virotherapy is a promising cancer treatment approach.
- Further strategies are being explored to optimize OV efficacy.
- Combination with immunotherapy holds significant potential for improving oncolytic virotherapy outcomes.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

